Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Bringing Order to Information Chaos Is a Necessity in the Age of COVID-19

Share on Stocktwits


Leonovus, a data storage and security technology firm, positions its software to enable healthcare groups to organize massive amounts of COVID/public health data.

The world is awash in data, and organizing it is often difficult. Ottawa-based Leonovus Inc. (LTV:TSX.V) has invested more than $40 million to develop a secure way to store sensitive information across hybrid and multi-cloud storage infrastructures in a technology it calls Vault, which is currently in the final trial phase in a major Canadian government department.

The trialing department is involved with thousands of unique, individual projects. "Currently, because of security and efficiency reasons, the customer is looking to manage data for each project using state of the art cloud data management and storage technologies, like our Vault and Smart Filer solutions," Leonovus Chairman and CEO Michael Gaffney told Streetwise Reports.

Leonovus software is for any large enterprise or institution that wants a highly secure way to manage, move or store data in the cloud or across a combination of in the cloud and on premises. "It's a hybrid data storage and data management strategy that's flexible to almost any current IT infrastructure and highly secure," Gaffney explained. "Vault uses patented algorithms to analyze, classify, encrypt, shred and spread data across a network of on-premises or multi-cloud storage nodes. From a governance perspective, Vault provides a single set of storage targets and ensures the application of a consistent set of security and compliance policies to all data stored."

In addition to the currently active trial, "Leonovus has proven the technologies of both Smart Filer and Vault with other departments in the federal public service," Gaffney said. "Another trial has been contracted to begin shortly with a large government department with strong security requirements. In addition to the government, Leonovus has had successful trials in several private sector companies in finance, marketing, resources and manufacturing."

Leonovus also sees value in its technology for the healthcare industry, especially during the pandemic. "In the U.S., Canada and around the world, public health has historically been the last place to get funded. As a direct result, the world's public health data management is currently not up to the state of the art. In the U.S., there's no central place where you can get all the data regarding COVID. It's piecemeal, stored in independent silos, and researchers, policymakers and hospital administrators are rightly complaining," Gaffney said. "We can take our Smart Filer technology and within minutes install it in any location that might have pandemic data, such as nursing homes, hospitals, schools, health centers, research facilities, universities, etc., any place that may have COVID data that should be in a centralized data lake."

"We have the data to be able to track and report COVID-19's progress across the globe, across countries and communities alike," Gaffney continued. "We have the communications, connectivity and computational power to model and track the spread of the virus and to model and comprehend its internal make-up and composition. We have the necessary data to track outbreaks and hot spots and the near-real time capability to take action mitigating and managing through containment while we work toward a cure. Similarly, we can track and monitor sample populations as we develop and apply treatments, prophylactic and curative. However, until now, there has been no path where the right data gets to the right people to take the right actions when they need to be done."

Leonovus' Consolidata solution solves this problem by creating a single data lake. "It's a massive amount of data: thousands of files from thousands of locations from thousands, and mostly likely millions of people," Gaffney explained.

One advantage of Consolidata is that it can be launched quickly, within a matter of weeks.

Leonovus chart

The firm is currently in discussion with several private and public sector healthcare organizations to begin using its technology.

Leonovus is helmed by an experienced team. Chairman and CEO Michael Gaffney brings more than 30 years of entrepreneurial experience with technology companies in semiconductors, telecommunications, eLearning, mobile technology, data storage, security software and blockchain technologies. Chief Technology Officer Daniel Willis founded Adscape Media, which was acquired by Google in 2007, and with over 35 years of software solutions, has more than 70 patent applications to his name. Sean O'Hagan, vice-president of engineering, has spent over 20 years developing software and solutions for the aerospace, telecommunications and enterprise software industries, and led the development of Leonovus' original product suite of cloud storage, compute and IoT technologies.

The company has approximately 285 million shares outstanding and trades on the TSX Venture Exchange under the symbol LTV.


1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Leonovus. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Leonovus, a company mentioned in this article.

Want to read more about Life Sciences Tools & Diagnostics and Technology investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe